Is PHG a good stock to buy right now?

Based on our 6-factor quantitative model, KONINKLIJKE PHILIPS NV (PHG) receives a "Reduce" rating with a composite score of 44.8/100. It is ranked #2,128 out of 4,446 stocks. Key factor scores: Quality 36/100, Value 45/100, Momentum 51/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for PHG?

KONINKLIJKE PHILIPS NV (PHG) has a "Reduce" rating and 2-star score. The composite score of 44.8 ranks it #2,128 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is PHG in?

KONINKLIJKE PHILIPS NV operates in the Healthcare sector (Medical Equipment industry) with a market cap of $25.96 billion. It is classified as a large-cap stock.

Does PHG pay a dividend?

PHG does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is PHG's P/E ratio?

P/E ratio data is not currently available for PHG, which may indicate the company is not yet profitable.

How profitable is PHG?

PHG's quality factor score is 36/100. Gross margin: 43.1%. ROE: -23.3% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is PHG valued compared to peers?

PHG's value factor score is 45/100 (higher = cheaper). Key multiples: , EV/EBITDA 14.2x. Valuation is roughly in line with peers.

What is PHG's debt level?

PHG's debt-to-equity ratio is 64%. Sector average: 32%. Moderate leverage is normal for established companies.

PHG has a beta of 0.94, meaning it tracks the market. Stability score: 71/100.

Does PHG have high short interest?

PHG's short interest factor score is 20/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

PHG Stock Analysis: Reduce (Score 44.8/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
PHG	+0.64%	+4.43%	-2.21%	+4.54%	+25.21%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.71%	+0.82%	-2.55%	+4.90%	-4.31%	-	-	-
Alpha vs Sector	+1.99%	+4.09%	+1.60%	+9.38%	+16.00%	-	-	-

Metric	PHG	Benchmark
P/E Ratio	-8.9x	-138%
EV/EBITDA	14.2x	+124%
Price / Book	2.1x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
PHG KONINKLIJKE PHILIPS NV	45	36	45	51	-	-23.3%	43.1%	-3.9%	12.2%	64.0x	$26.0B

Key Ratio	TTM	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.4%	0.4%	0.4%	0.4%	0.4%	0.5%	0.5%	0.5%	0.5%	0.5%
Operating Margin %	0.1%	0.1%	-0.0%	-0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.0%	0.0%	-0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%
Net Margin %	-0.0%	-0.0%	-0.0%	-0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	-9.4%	-9.4%	1.7%	-40.3%	-63.1%	5.4%	-6.0%	8.6%	26.6%	-105.0%
ROE %	-0.2%	-0.1%	-0.0%	-0.2%	0.6%	0.0%	6.6%	5.9%	0.2%	0.1%
ROA %	-0.1%	-0.0%	-0.0%	-0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.0%
ROIC %	3.8%	3.8%	1.5%	-8.9%	4.3%	3.4%	29.2%	40.9%	8.0%	4.0%

Key Ratio

TTM

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.4%

0.5%

Operating Margin %

0.1%

-0.0%

-0.1%

0.0%

0.1%

EBITDA Margin %

0.0%

-0.0%

0.0%

0.1%

Net Margin %

-0.0%

-0.1%

0.2%

0.1%

FCF Margin %

-9.4%

1.7%

-40.3%

-63.1%

5.4%

-6.0%

8.6%

26.6%

-105.0%

ROE %

-0.2%

-0.1%

-0.0%

-0.2%

0.6%

0.0%

6.6%

5.9%

0.2%

0.1%

ROA %

-0.1%

-0.0%

-0.1%

0.1%

0.0%

0.1%

0.0%

ROIC %

3.8%

1.5%

-8.9%

4.3%

3.4%

29.2%

40.9%

8.0%

4.0%

Line Item	TTM	2024	2023	2022	2021	2020	2019	2018	2017	2016
	$18.7B	$18.7B	$20.1B	$19.1B	$19.4B	$21.1B	$19.2B	$20.7B	$21.4B	$18.3B
	$8.0B	$8.0B	$8.2B	$7.7B	$8.1B	$9.6B	$8.9B	$9.8B	$9.8B	$8.4B
Gross Margin	43.1%	43.1%	41.0%	40.4%	41.8%	45.2%	46.1%	47.2%	46.0%	45.6%
	—	$1.8B	$2.1B	$2.2B	$2.0B	$2.2B	$2.0B	$2.0B	$2.1B	$1.8B
Depreciation	—	$0	$0	$0	$1.5B	$0	$1.6B	$1.2B	$1.2B	$1.0B
	$863M	$863M	$363M	-$1.7B	$626M	$1.4B	$1.5B	$2.0B	$1.8B	$1.5B
EBIT	$1.4B	$863M	$363M	-$1.7B	$626M	$1.4B	$1.5B	$2.0B	$1.8B	$1.5B
EBITDA	$548M	$548M	-$236M	$79M	$626M	$1.7B	$1.5B	$2.0B	$3.0B	$2.6B
Operating Margin	5.3%	5.3%	-1.3%	-8.7%	2.9%	7.4%	7.1%	9.5%	7.7%	8.4%
EBITDA Margin	2.9%	2.9%	-1.2%	0.4%	3.2%	8.1%	8.0%	9.5%	14.3%	14.2%
	—	$401M	$416M	$276M	$213M	$247M	$261M	$302M	$316M	$533M
	—	$997M	-$81M	-$121M	$117M	$259M	$290M	$221M	$419M	$214M
	-$722M	-$722M	-$512M	-$1.7B	$3.8B	$1.5B	$1.3B	$1.3B	$2.2B	$1.6B
Net Margin	-3.9%	-3.9%	-2.5%	-9.0%	19.4%	6.9%	6.8%	6.0%	10.5%	8.6%
	-	-	-	$-1.75	$3.67	$1.31	$1.27	$1.18	$1.78	$1.58
Diluted EPS	-	-	-	$-1.75	$3.67	$1.31	$1.27	$1.18	$1.78	$1.58

Line Item

TTM

2024

2023

2022

2021

2020

2019

2018

2017

2016

$18.7B

$20.1B

$19.1B

$19.4B

$21.1B

$19.2B

$20.7B

$21.4B

$18.3B

$8.0B

$8.2B

$7.7B

$8.1B

$9.6B

$8.9B

$9.8B

$8.4B

Gross Margin

43.1%

41.0%

40.4%

41.8%

45.2%

46.1%

47.2%

46.0%

45.6%

—

$1.8B

$2.1B

$2.2B

$2.0B

$2.2B

$2.0B

$2.1B

$1.8B

Depreciation

—

$1.5B

$1.6B

$1.2B

$1.0B

$863M

$363M

-$1.7B

$626M

$1.4B

$1.5B

$2.0B

$1.8B

$1.5B

EBIT

$1.4B

$863M

$363M

-$1.7B

$626M

$1.4B

$1.5B

$2.0B

$1.8B

$1.5B

EBITDA

$548M

-$236M

$79M

$626M

$1.7B

$1.5B

$2.0B

$3.0B

$2.6B

Operating Margin

5.3%

-1.3%

-8.7%

2.9%

7.4%

7.1%

9.5%

7.7%

8.4%

EBITDA Margin

2.9%

-1.2%

0.4%

3.2%

8.1%

8.0%

9.5%

14.3%

14.2%

—

$401M

$416M

$276M

$213M

$247M

$261M

$302M

$316M

$533M

—

$997M

-$81M

-$121M

$117M

$259M

$290M

$221M

$419M

$214M

-$722M

-$512M

-$1.7B

$3.8B

$1.5B

$1.3B

$2.2B

$1.6B

Net Margin

-3.9%

-2.5%

-9.0%

19.4%

6.9%

6.8%

6.0%

10.5%

8.6%

$-1.75

$3.67

$1.31

$1.27

$1.18

$1.78

$1.58

Diluted EPS

$-1.75

$3.67

$1.31

$1.27

$1.18

$1.78

$1.58

KONINKLIJKE PHILIPS NV (PHG) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does KONINKLIJKE PHILIPS NV Do?

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands. KONINKLIJKE PHILIPS NV (PHG) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Roy Jakobs and employs approximately 78,200 people. With a market capitalization of $26.0B, PHG is one of the prominent companies in the Healthcare sector.

KONINKLIJKE PHILIPS NV (PHG) Stock Rating — Reduce (April 2026)

As of April 2026, KONINKLIJKE PHILIPS NV receives a Reduce rating with a composite score of 44.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PHG ranks #2,128 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, KONINKLIJKE PHILIPS NV ranks #242 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PHG Stock Price and 52-Week Range

KONINKLIJKE PHILIPS NV (PHG) currently trades at $28.31. The stock gained $0.18 (0.6%) in the most recent trading session. The 52-week high for PHG is $33.44, which means the stock is currently trading -15.3% from its annual peak. The 52-week low is $21.48, putting the stock 31.8% above its annual trough. Recent trading volume was 849K shares, suggesting relatively thin trading activity.

Is PHG Overvalued or Undervalued? — Valuation Analysis

KONINKLIJKE PHILIPS NV (PHG) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 2.07x, versus the sector average of 2.75x. The price-to-sales ratio is 0.34x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PHG trades at 14.21x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 22.06x.

Overall, PHG's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

KONINKLIJKE PHILIPS NV Profitability — ROE, Margins, and Quality Score

KONINKLIJKE PHILIPS NV (PHG) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -23.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -9.6% versus the sector average of -33.1%.

On a margin basis, KONINKLIJKE PHILIPS NV reports gross margins of 43.1%, compared to 71.5% for the sector. The operating margin is 5.3% (sector: -66.1%). Net profit margin stands at -3.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 12.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PHG Debt, Balance Sheet, and Financial Health

KONINKLIJKE PHILIPS NV has a debt-to-equity ratio of 64.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. Total debt on the balance sheet is $7.91B. Cash and equivalents stand at $2.49B.

PHG has a beta of 0.94, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for KONINKLIJKE PHILIPS NV is 71/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

KONINKLIJKE PHILIPS NV Revenue and Earnings History — Quarterly Trend

In TTM 2026, KONINKLIJKE PHILIPS NV reported revenue of $18.65B. Net income for the quarter was $-722M. Gross margin was 43.1%. Operating income came in at $863M.

In FY 2024, KONINKLIJKE PHILIPS NV reported revenue of $18.65B. Net income for the quarter was $-722M. Gross margin was 43.1%. Revenue grew -7.2% year-over-year compared to FY 2023. Operating income came in at $863M.

In FY 2023, KONINKLIJKE PHILIPS NV reported revenue of $20.10B. Net income for the quarter was $-512M. Gross margin was 41.0%. Revenue grew 5.4% year-over-year compared to FY 2022. Operating income came in at $363M.

In FY 2022, KONINKLIJKE PHILIPS NV reported revenue of $19.07B and earnings per share (EPS) of $-1.75. Net income for the quarter was $-1.72B. Gross margin was 40.4%. Revenue grew -1.8% year-over-year compared to FY 2021. Operating income came in at $-1.65B.

Over the past 8 quarters, KONINKLIJKE PHILIPS NV has experienced revenue contraction from $20.74B to $18.65B. Investors analyzing PHG stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PHG Dividend Yield and Income Analysis

KONINKLIJKE PHILIPS NV (PHG) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PHG Momentum and Technical Analysis Profile

KONINKLIJKE PHILIPS NV (PHG) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 55/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PHG vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, KONINKLIJKE PHILIPS NV (PHG) ranks #242 out of 838 stocks based on the Blank Capital composite score. This places PHG in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PHG against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PHG vs S&P 500 (SPY) comparison to assess how KONINKLIJKE PHILIPS NV stacks up against the broader market across all factor dimensions.

PHG Next Earnings Date

No upcoming earnings date has been announced for KONINKLIJKE PHILIPS NV (PHG) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PHG? — Investment Thesis Summary

The quantitative profile for KONINKLIJKE PHILIPS NV suggests caution. The quality score of 36/100 flags below-average profitability. Low volatility (stability score 71/100) reduces downside risk.

In summary, KONINKLIJKE PHILIPS NV (PHG) earns a Reduce rating with a composite score of 44.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PHG stock.

Related Resources for PHG Investors

Explore more research and tools: PHG vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PHG head-to-head with peers: PHG vs AZN, PHG vs SLGL, PHG vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Unpacking Q4 Earnings: Universal Display (NASDAQ:OLED) In The Context Of Other Analog Semiconductors Stocks

Here's Why Royal Philips (PHG) is a Strong Value Stock

Food Processor Market Trends, Opportunities, Competition and Growth Outlook 2026-2035 - Industry Expected to Reach USD 3.7 Billion by 2035, Driven by Demand for Efficient Kitchen Appliances

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

A Look At Koninklijke Philips (ENXTAM:PHIA) Valuation After Recent Share Price Moves

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

KONINKLIJKE PHILIPS NV (PHG) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does KONINKLIJKE PHILIPS NV Do?

KONINKLIJKE PHILIPS NV (PHG) Stock Rating — Reduce (April 2026)

PHG Stock Price and 52-Week Range

Is PHG Overvalued or Undervalued? — Valuation Analysis

KONINKLIJKE PHILIPS NV Profitability — ROE, Margins, and Quality Score

PHG Debt, Balance Sheet, and Financial Health

KONINKLIJKE PHILIPS NV Revenue and Earnings History — Quarterly Trend

PHG Dividend Yield and Income Analysis

PHG Momentum and Technical Analysis Profile

PHG vs Competitors — Healthcare Sector Ranking and Peer Comparison

PHG Next Earnings Date

Should You Buy PHG? — Investment Thesis Summary

Related Resources for PHG Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Unpacking Q4 Earnings: Universal Display (NASDAQ:OLED) In The Context Of Other Analog Semiconductors Stocks

Here's Why Royal Philips (PHG) is a Strong Value Stock

Food Processor Market Trends, Opportunities, Competition and Growth Outlook 2026-2035 - Industry Expected to Reach USD 3.7 Billion by 2035, Driven by Demand for Efficient Kitchen Appliances

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

A Look At Koninklijke Philips (ENXTAM:PHIA) Valuation After Recent Share Price Moves